文献速递免疫规划传染病防控与疫情报告

合成糖偶联疫苗与卡介苗联合接种对小鼠结核产生协同保护作用

Co-administration of a synthetic saccharide conjugate vaccine with BCG provides synergistic protection against murine tuberculosis.
PubMed 文献 · Vaccine · 2025-10-29

该研究在小鼠体内首次评估卡介苗与针对分枝杆菌细胞包膜PIMs保守末端甘露糖序列的新型合成糖偶联疫苗联合接种,结果显示联合接种较单用卡介苗降低细菌负荷,提示靶向分枝杆菌保守必需寡糖可能改善结核疫苗效力。

要点

  • 卡介苗与合成糖偶联疫苗联合接种较单用卡介苗降低小鼠细菌负荷。
  • 该合成糖偶联疫苗靶向分枝杆菌PIMs中保守末端甘露糖序列。
  • 这是该联合策略的首个体内效力研究,提示靶向保守寡糖可改善疫苗效力。

核心结论

  • 卡介苗与新型合成糖偶联疫苗联合接种较单用卡介苗降低细菌负荷。
  • 靶向分枝杆菌保守必需寡糖可能是改善结核疫苗效力的重要因素。

研究设计与样本

  • 该研究为小鼠体内效力研究,首次评估卡介苗与合成糖偶联疫苗联合接种。

主要发现

  • 联合接种组较单用卡介苗组细菌负荷降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis (TB) remains a major global health challenge claiming over 1 million lives annually. Bacillus Calmette-Guérin (BCG), the only licensed vaccine against TB, provides limited efficacy against pulmonary TB in adults and only partial protection against serious disease in children. Hence, the development of safer and more effective new vaccines against TB remains a global health priority. Here we show in a new approach that co-administration of BCG with a novel synthetic glycan conjugate vaccine, corresponding to conserved terminal mannose sequences in Phosphatidyl-myo-inositol-mannosides (PIMs) in the cell envelope of mycobacteria, results in reduced bacterial burden compared to BCG vaccination alone. This first in vivo efficacy study suggests that targeting conserved essential oligosaccharides of mycobacteria is an important factor in improving TB vaccine efficacy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Miranda-Hernandez S, Sathkumara HD, Zhao G, et al. Co-administration of a synthetic saccharide conjugate vaccine with BCG provides synergistic protection against murine tuberculosis. Vaccine. 2025. PMID: 41167016. doi:10.1016/j.vaccine.2025.127912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。